Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Follow-Up Questions
What is the price performance of PTPI stock?
The current price of PTPI is $0.0234, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Petros Pharmaceuticals Inc?
Petros Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Petros Pharmaceuticals Inc market cap?
Petros Pharmaceuticals Inc's current market cap is $991.4K
Is Petros Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Petros Pharmaceuticals Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
